title: Initial treatment of Parkinson's disease: an update.
abstract: This is an update to an article published in this journal in 2006, which covered the initial treatment of Parkinson's disease (PD). In this update, we review new research into symptomatic treatments, potential disease modifying ("neuroprotective") agents, and evidence-based reviews of current treatment. We discuss the usage of the MAO-B inhibitors, including the controversy surrounding the possible neuroprotective effects of rasagiline. Usage of extended release formulations of pramipexole and ropinirole, as well as the transdermal dopamine agonist rotigotine, are reviewed. Side effects of the dopamine agonists are discussed, including the cardiac side effects of ergot-derived dopamine agonists, and the impulse control disorders associated with the dopamine agonists. The use of zonisamide as an agent for PD tremor is reviewed. We touch on the clinical research into the benefits of exercise in PD, and briefly review some of the current studies for new formulations of levodopa and other medications and treatments with novel mechanisms of action.
authors: Department of Neurology, Harvard Medical School, Parkinson's Disease and Movement Disorders Center, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA, 02215, USA.
authors: Scott
authors: S
authors: Kaplan
authors: Daniel
authors: D
authors: Tarsy
references: Neurology. 2007 Apr 3;68(14):1108-15
references: 17404192
references: Mov Disord. 2011 Jan;26(1):90-9
references: 21322021
references: Neurology. 2010 Apr 6;74(14):1143-8
references: 20368634
references: JAMA Neurol. 2013 Feb;70(2):183-90
references: 23128427
references: N Engl J Med. 2007 Jan 4;356(1):39-46
references: 17202454
references: Arch Neurol. 2006 Jul;63(7):969-73
references: 16831966
references: Lancet Neurol. 2007 Jun;6(6):513-20
references: 17509486
references: Mov Disord. 2010 Nov 15;25(15):2542-9
references: 20669317
references: Neurology. 2006 Jun 13;66(11):1750-2
references: 16769956
references: Mov Disord. 2011 Oct;26(12):2246-52
references: 21755537
references: Clin Ther. 2007 Dec;29(12):2654-66
references: 18201581
references: No To Shinkei. 2003 Aug;55(8):685-9
references: 13677302
references: Neurorehabil Neural Repair. 2009 Jul-Aug;23(6):600-8
references: 19131578
references: Arch Neurol. 2004 Apr;61(4):561-6
references: 15096406
references: Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S147-50
references: 22166417
references: N Engl J Med. 2012 Feb 9;366(6):511-9
references: 22316445
references: Curr Treat Options Neurol. 2006 May;8(3):224-35
references: 16569381
references: Lancet Neurol. 2011 May;10(5):415-23
references: 21482191
references: N Engl J Med. 2007 Jan 4;356(1):29-38
references: 17202453
references: Neurology. 2011 Aug 23;77(8):767-74
references: 21832216
references: Clin Neuropharmacol. 2007 Sep-Oct;30(5):256-65
references: 17909303
references: Neurology. 2007 Jan 23;68(4):272-6
references: 17202432
references: Eur J Neurol. 2013 Jan;20(1):50-6
references: 22537207
references: Neurology. 2011 Aug 23;77(8):759-66
references: 21832218
references: Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004898
references: 16034956
references: Mov Disord. 2007 Dec;22(16):2398-404
references: 17935234
references: Mov Disord. 2011 Oct;26 Suppl 3:S42-80
references: 22021174
references: Neurology. 2009 Apr 14;72(15):1352-7
references: 19365057
references: Mov Disord. 2010 Oct 30;25(14):2326-32
references: 20669265
references: Arch Neurol. 2007 Dec;64(12):1721-6
references: 18071034
references: Mov Disord. 2012 Feb;27(2):242-7
references: 22134954
references: Int J Neurosci. 2011;121 Suppl 2:53-62
references: 22035030
references: Clin Neuropharmacol. 2012 Jul-Aug;35(4):174-81
references: 22801294
references: Mov Disord. 2006 Oct;21(10):1716-21
references: 16856145
references: Neurology. 2011 Jul 19;77(3):288-94
references: 21768599
references: N Engl J Med. 2009 Sep 24;361(13):1268-78
references: 19776408
references: Mov Disord. 2010;25 Suppl 1:S141-5
references: 20187247
references: Mov Disord. 2007 Oct 31;22(14):2137-8
references: 17853481
references: Arch Neurol. 2010 May;67(5):589-95
references: 20457959
references: Eur J Neurol. 2013 Jan;20(1):180-7
references: 22845710
references: Clin Neuropharmacol. 2009 May-Jun;32(3):140-8
references: 18978485